Adenoviral Pneumonia During Etanercept Treatment in a Patient with Rheumatoid Arthritis.
10.3904/kjim.2007.22.1.63
- Author:
Min Jung KANG
1
;
Myung Sin KIM
;
Eun Hwa CHOI
;
Kyoung Eun LEE
;
You Kyoung KIM
;
Hee Jung CHOI
Author Information
1. Department of Internal Medicine, College of Medicine, Ewha Womans University, Seoul, Korea. heechoi@ewha.ac.kr
- Publication Type:Case Report
- Keywords:
Tumor Necrosis Factor-alpha;
Pneumonia;
Adenovirus Infections;
Human;
TNFR-Fc fusion protein
- MeSH:
Risk Factors;
Recombinant Fusion Proteins/immunology;
Receptors, Tumor Necrosis Factor/immunology;
Middle Aged;
Immunoglobulin G/*adverse effects/immunology;
Immunocompromised Host/drug effects;
Humans;
Female;
Arthritis, Rheumatoid/*drug therapy;
Antirheumatic Agents/*adverse effects/immunology;
Antibodies, Monoclonal/*adverse effects/immunology;
Adenovirus Infections, Human/*etiology/immunology
- From:The Korean Journal of Internal Medicine
2007;22(1):63-66
- CountryRepublic of Korea
- Language:English
-
Abstract:
Inhibitors of tumor necrosis factor-alpha (TNF-alpha) have been approved for treating rheumatoid arthritis. As one of the biological response modifiers, etanercept has also been used in the treatment of psoriatic arthritis and inflammatory bowel disease. While etanercept is effective, certain infectious complications, such as tuberculosis, fungus, and cytomegalovirus, have been reported. We report the first Korean case of adenoviral pneumonia in a 55-year-old female who developed disseminated adenoviral infection following etanercept treatment, which resolved after anti-TNF-alpha discontinuation.
